X-Ray Apparatus & Tubes & Related Irradiation Apparatus
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Sector
Discounted Cash Flow Valuation of Ge Healthcare Technologies Inc.
Growth
%
%
Discount
%
%
Multiple
g\r | +10% | +11% | +12% | +13% | +14% |
---|---|---|---|---|---|
0% | 10 | 9 | 8 | 8 | 7 |
+1% | 11 | 10 | 9 | 8 | 8 |
+2% | 13 | 11 | 10 | 9 | 8 |
+3% | 14 | 13 | 11 | 10 | 9 |
+4% | 17 | 14 | 12 | 11 | 10 |
Years | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | TV |
---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF | $1.663B | $1.559B | $1.462B | $1.37B | $1.285B | $1.205B | $1.129B | $1.059B | $992.6M | $930.6M | $872.5M | $8.725B |
DCF | $1.356B | $1.105B | $901.1M | $734.6M | $598.9M | $488.2M | $398M | $324.5M | $264.5M | $215.7M | $2.157B | |
Value | $8.543B |
In the chart Earnings are multiplied by this value.
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
Years | 12-2021 | 12-2022 | 12-2023 | TTM |
---|---|---|---|---|
Net Margin | 13% | 10% | 7.1% | 8.1% |
ROA | - | 9.2% | 7.5% | 7.5% |
ROE | 13% | 20% | 19% | 21% |
The average Net Margin over the past 5 years is +10.1%.
The trend of Net Margin over the past 5 years is -2.85%.
The average ROA over the past 5 years is +8.33%.
The trend of ROA over the past 5 years is -1.65%.
The average ROE over the past 5 years is +17.77%.
The trend of ROE over the past 5 years is +2.95%.
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
Years | 12-2021 | 12-2022 | 12-2023 | TTM | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Debt FCF | - | 4.55 | 6.10 | 6.20 | ||||||
Debt Equity | - | 0.89 | 1.46 | 1.39 | ||||||
MIN | ||||||||||
Graham Stability | - | - | - | - |
The Debt/FCF trailing twelve month is 6.20.
The trend of Debt/FCF over the past 5 years is 1.55.
Graham’s Stability measure stands at -.
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
Years | 12-2022 | Trend |
---|---|---|
Revenue | 6.6% | 2.3% |
Net Income | -28% | -13% |
Stockholders Equity | -24% | 20% |
FCF | -6% | -40% |
The Revenue CAGR over the past 5 years is -.
The trend of Revenue growth rate over the past 5 years is +2.3%.
The Earnings CAGR over the past 5 years is -.
The trend of Earnings growth rate over the past 5 years is -12.98%.
The Equity CAGR over the past 5 years is -.
The trend of Equity growth rate over the past 5 years is +20.18%.
The FCF CAGR over the past 5 years is -.
The trend of FCF growth rate over the past 5 years is -40.25%.